Works matching AU Steeghs, N.

Results: 17

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.

Published in:

British Journal of Cancer, 2015, v. 112, n. 6, p. 1011, doi. 10.1038/bjc.2015.82

By:

Kloth, J S L;
Pagani, A;
Verboom, M C;
Malovini, A;
Napolitano, C;
Kruit, W H J;
Sleijfer, S;
Steeghs, N;
Zambelli, A;
Mathijssen, R H J

Publication type:

Article

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.

Published in:

2015

By:

Kloth, J S L;
Pagani, A;
Verboom, M C;
Malovini, A;
Napolitano, C;
Kruit, W H J;
Sleijfer, S;
Steeghs, N;
Zambelli, A;
Mathijssen, R H J

Publication type:

journal article

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Published in:

British Journal of Cancer, 2014, v. 110, n. 10, p. 2441, doi. 10.1038/bjc.2014.194

By:

Lankheet, N A G;
Kloth, J S L;
Gadellaa-van Hooijdonk, C G M;
Cirkel, G A;
Mathijssen, R H J;
Lolkema, M P J K;
Schellens, J H M;
Voest, E E;
Sleijfer, S;
de Jonge, M J A;
Haanen, J B A G;
Beijnen, J H;
Huitema, A D R;
Steeghs, N

Publication type:

Article

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Published in:

2010

By:

Hamberg, P.;
Steeghs, N.;
Loos, W. J.;
van de Biessen, D.;
den Hollander, M.;
Tascilar, M.;
Verweij, J.;
Gelderblom, H.;
Sleijfer, S.

Publication type:

journal article

Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.

Published in:

Supportive Care in Cancer, 2025, v. 33, n. 3, p. 1, doi. 10.1007/s00520-025-09248-5

By:

Roets, E.;
Younger, E.;
Jones, R. L.;
Hollander, D.den;
Desar, I. M. E.;
Young, R. J.;
Oosten, A. W.;
de Haan, J. J.;
Gelderblom, H.;
Steeghs, N.;
van der Graaf, W. T. A.;
Husson, O.

Publication type:

Article

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.

Published in:

2018

By:

Koldenhof, J. J.;
Lankheet, N. A. G.;
Steeghs, N.;
Teunissen, S. C. C. M.;
Witteveen, P. O.

Publication type:

journal article

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 353, doi. 10.1007/s00280-023-04615-7

By:

Westerdijk, K.;
Krens, S. D.;
Steeghs, N.;
van der Graaf, W. T. A.;
Tjwa, E. T. T. L.;
Westdorp, H.;
Desar, I. M. E.;
van Erp, N. P.

Publication type:

Article

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 447, doi. 10.1007/s00280-023-04517-8

By:

Groenland, Stefanie L.;
Janssen, J. M.;
Nijenhuis, C. M.;
de Vries, N.;
Rosing, H.;
Wilgenhof, S.;
van Thienen, J. V.;
Haanen, J. B. A. G.;
Blank, C. U.;
Beijnen, J. H.;
Huitema, A. D. R.;
Steeghs, N.

Publication type:

Article

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.

Published in:

2021

By:

Verheijen, R. B.;
van Duijl, T. T.;
van den Heuvel, M. M.;
Vessies, D.;
Muller, M.;
Beijnen, J. H.;
Janssen, J. M.;
Schellens, J. H. M.;
Steeghs, N.;
van den Broek, D.;
Huitema, A. D. R.

Publication type:

journal article

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Published in:

2020

By:

Verheijen, R. B.;
Swart, E. L.;
Beijnen, J. H.;
Schellens, J. H. M.;
Huitema, A. D. R.;
Steeghs, N.

Publication type:

Correction Notice

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Published in:

2017

By:

Verheijen, R.;
Swart, L.;
Beijnen, J.;
Schellens, J.;
Huitema, A.;
Steeghs, N.;
Verheijen, R B;
Swart, L E;
Beijnen, J H;
Schellens, J H M;
Huitema, A D R

Publication type:

journal article

C-reactive protein and D-dimer with clinical probability score in the exclusion of pulmonary embolism.

Published in:

British Journal of Haematology, 2005, v. 130, n. 4, p. 614, doi. 10.1111/j.1365-2141.2005.05652.x

By:

Steeghs, N.;
Goekoop, R. J.;
Niessen, R. W. L. M.;
Jonkers, G. J. P. M.;
Dik, H.;
Huisman, M. V.

Publication type:

Article

The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib.

Published in:

CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2557, doi. 10.1111/cts.13647

By:

van der Heijden, L. T.;
Steeghs, N.;
Beijnen, J. H.;
Huitema, A. D. R.;
Dorlo, T. P. C.

Publication type:

Article

Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline <italic>KIT</italic>-Trp557Arg mutation: case report and literature overview.

Published in:

Familial Cancer, 2018, v. 17, n. 2, p. 247, doi. 10.1007/s10689-017-0024-8

By:

Farag, S.;
van der Kolk, L. E.;
van Boven, H. H.;
van Akkooi, A. C. J.;
Beets, G. L.;
Wilmink, J. W.;
Steeghs, N.

Publication type:

Article

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662.

Published in:

Clinical Pharmacology & Therapeutics, 2014, v. 96, n. 1, p. 81, doi. 10.1038/clpt.2014.47

By:

Diekstra, M H M;
Klümpen, H J;
Lolkema, M P J K;
Yu, H;
Kloth, J S L;
Gelderblom, H;
Schaik, R H N;
Gurney, H;
Swen, J J;
Huitema, A D R;
Steeghs, N;
Mathijssen, R H J

Publication type:

Article

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.

Published in:

Acta Oncologica, 2017, v. 56, n. 1, p. 88, doi. 10.1080/0284186X.2016.1234068

By:

Kollár, A.;
Duffaud, F.;
Sleijfer, S.;
Touati, N.;
Litière, S.;
Marreaud, S.;
Gronchi, A.;
Kasper, B.;
Jones, R. L.;
van der Graaf, W. T.;
Stacchiotti, S.;
Gelderblom, H.;
Guida, M.;
Grignani, G.;
Steeghs, N.;
Safwat, A.;
Katz, D.

Publication type:

Article

Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnership.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12732-6

By:

Roets, E.;
Schuster, K.;
Bickley, S.;
Wartenberg, M.;
Gonzato, O.;
Fernandez, N.;
Kasper, B.;
Pilgermann, K.;
Wilson, R.;
Steeghs, N.;
van der Graaf, W. T. A.;
van Oortmerssen, G.;
Husson, O.

Publication type:

Article